|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-12-26
|
|
pubmed:abstractText |
Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. The possibility that intentional targeting of tumor antigens representing normal proteins can result in autoimmune toxicity has been postulated but never demonstrated previously in humans. In this study, we describe a patient with metastatic melanoma who developed inflammatory lesions circumscribing pigmented areas of skin after an infusion of MART-1-specific CD8(+) T cell clones. Analysis of the infiltrating lymphocytes in skin and tumor biopsies using T cell-specific peptide-major histocompatibility complex tetramers demonstrated a localized predominance of MART-1-specific CD8(+) T cells (>28% of all CD8 T cells) that was identical to the infused clones (as confirmed by sequencing of the complementarity-determining region 3). In contrast to skin biopsies obtained from the patient before T cell infusion, postinfusion biopsies demonstrated loss of MART-1 expression, evidence of melanocyte damage, and the complete absence of melanocytes in affected regions of the skin. This study provides, for the first time, direct evidence in humans that antigen-specific immunotherapy can target not only antigen-positive tumor cells in vivo but also normal tissues expressing the shared tumor antigen.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-10077623,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-10203037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-10371507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-1424750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-1643151,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-1645450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-1691237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-3631983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-7516411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-7887661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-8170938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-8810254,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-8859727,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9053445,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9122734,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9500606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9500607,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9545200,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9551367,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9565629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9743539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9862627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11104805-9973498
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
192
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1637-44
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11104805-Antigens, Neoplasm,
pubmed-meshheading:11104805-Female,
pubmed-meshheading:11104805-Humans,
pubmed-meshheading:11104805-Immunotherapy, Adoptive,
pubmed-meshheading:11104805-MART-1 Antigen,
pubmed-meshheading:11104805-Melanocytes,
pubmed-meshheading:11104805-Melanoma,
pubmed-meshheading:11104805-Middle Aged,
pubmed-meshheading:11104805-Neoplasm Proteins,
pubmed-meshheading:11104805-Skin,
pubmed-meshheading:11104805-Skin Neoplasms,
pubmed-meshheading:11104805-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11104805-Vitiligo
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
|
|
pubmed:affiliation |
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Case Reports,
Research Support, Non-U.S. Gov't
|
